Juno Therapeutics, Inc. (Nasdaq: JUNO)

Celgeng is looking to purchase Juno Therapeutics, just one week after it announced that it was taking over Impact Biomedicines in a $7 billion transaction. Terms of the deal remain undisclosed, but Juno had a market value of about $5.5 billion as of 1/16/18 afternoon. Juno (NASDAQ: JUNO) shares surged more than 44 percent after-hours following the report. The Seattle company was trading at $65.98 a share at 5:19 p.m., with a market value of roughly $5.2 billion. Celgene shares fell about 0.7 percent.

If you are a current shareholder and would like to discuss your options of exercising your rights as a shareholder, which include ensuring that the company is getting the highest possible price for the company, and that the board of directors will act in the best interest of the shareholders, please contact us.

Please submit the following information so we can determine if you qualify for the suit. If you don't know all the specific details, partial information is also acceptable.

Personal Information
Phone #:
E-mail Address:
Stock Information
Do you currently own the stock? Yes   No
Purchase Date:
Quantity Purchased:
Purchase Price Per Share:

Please Note: Neither the submission to nor the receipt of information by The Law Offices of Marc S. Henzel or one of its attorneys through this website constitutes an agreement by the firm to represent the individual and does not create an attorney-client relationship.